Daily Medication Pearl: Lifitegrast Ophthalmic Solution (Xiidra)

Article

Lifitegrast ophthalmic solution (Xiidra) 5% is indicated for the treatment of the signs and symptoms of dry eye disease.

Medication Pearl of the Day: Lifitegrast Ophthalmic Solution (Xiidra)

Indication: Lifitegrast ophthalmic solution (Xiidra) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Insight:

  • Dosing: One drop twice daily in each eye (approximately 12 hours apart).
  • Dosage forms: Ophthalmic solution containing lifitegrast 5% (50 mg/mL).
  • Adverse events: The most common adverse reactions (incidence 5%-25%) following the use of Xiidra were instillation site irritation, dysgeusia, and decreased visual acuity.
  • Mechanism of action: Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1).
  • Manufacturer: Shire

Sources:

label (fda.gov)

xiidra image - Google Search

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.